Life Sciences Business Development Training Course

Name: Life Sciences Business Development and Licensing Training Course
Availability: InStock

Evaluate life sciences assets, licensing economics, deal terms, negotiation positions, and alliance governance through case-led tools.

Life Sciences Business Development Training Course

At a glance

Duration: 1 Week
Format: Classroom
Cities: Paris, Trabzon, Amman, Abu Dhabi, Milan, Frankfurt and more
Next session: 9 – 13 November 2026, Paris
Average fee: 5,750 €

Home
Our Categories
Life Sciences Business Development and Licensing Training Course

Download Brochure (PDF) Print PDF

Overview

Life Sciences Business Development and Licensing Training Course is a one-week advanced course for professionals who leave with a Life Sciences Partnering and Deal Portfolio. Participants connect therapeutic-area strategy, scientific and commercial due diligence, intellectual property licensing, risk-adjusted net present value, negotiation, and an alliance governance plan. Case-led analysis turns fragmented evidence into reviewable partnering decisions. Agile Leaders Training Center develops life sciences business development capability.

Who Should Attend

Functions responsible for sourcing and qualifying biotechnology or pharmaceutical assets
Teams responsible for licensing, partnering, and transaction development
Functions responsible for alliance governance and post-deal performance
Commercial teams responsible for therapeutic-area and market evaluation
Innovation and technology-transfer teams responsible for intellectual property commercialization

The course assumes participants already evaluate commercial opportunities or partnerships and leaves out legal advice, clinical judgment, regulatory submissions, and investment recommendations.

Departments and Industries

The course supports departments and industries where scientific assets move through partnering, licensing, and commercialization decisions.

Biotechnology and pharmaceutical business development
Medical technology and diagnostics commercialization
Research institutions and technology-transfer functions
Licensing, alliance management, and corporate strategy
Healthcare investment analysis and innovation functions

Learning Objectives

By the end of this course, participants will be able to:

Analyze therapeutic-area priorities and partnering options.
Build scientific, commercial, and intellectual property diligence plans.
Use risk-adjusted valuation and comparable-deal evidence.
Evaluate licensing economics and deal structures.
Apply negotiation methods to term-sheet positions.
Build alliance governance and transition plans.

Course Agenda

Day 1: Frame the Partnering Strategy

Therapeutic-Area Attractiveness and Strategic-Fit Matrix
Asset Development-Stage and Evidence Map
Partnering Thesis and Opportunity Screening Scorecard
Partner Landscape and Capability Comparison Grid
In-Licensing, Out-Licensing, and Collaboration Pathway Decision Tree

Day 2: Structure Due Diligence

Scientific Evidence and Development-Risk Review Framework
Commercial Opportunity and Patient-Market Assumption Register
Intellectual Property Chain-of-Title and Freedom-to-Operate Checklist
Partner Capability, Conflict, and Reputation Review
Cross-Functional Diligence Workplan and Red-Flag Log

Day 3: Value the Life Sciences Asset

Development Cost, Timing, and Probability-of-Success Assumption Sheet
Risk-Adjusted Net Present Value Model
Comparable Licensing Deal Selection Method
Milestone, Royalty, and Exclusivity Scenario Table
Valuation Range, Sensitivity, and Evidence Memorandum

Day 4: Design and Negotiate the Deal

License Scope, Territory, Field-of-Use, and Sublicensing Architecture
Upfront, Milestone, Royalty, and Cost-Sharing Term Map
Negotiation Mandate and Concession Exchange Matrix
Term-Sheet Position and Decision-Rights Checklist
Alliance Governance, Escalation, and Transition Blueprint

Day 5: Practice Partnering Decisions

Suggested Exercise: Screen a Biotechnology Asset Against the Partnering Thesis
Suggested Exercise: Triage Scientific, Commercial, and Intellectual Property Red Flags
Suggested Exercise: Defend a Valuation Range Under Alternative Development Scenarios
Suggested Exercise: Negotiate a Licensing Term-Sheet Position
Capstone Exercise: Present the Life Sciences Partnering and Deal Portfolio

Practical Exercises

The course uses suggested activities to connect life sciences evidence, valuation assumptions, licensing terms, and alliance decisions.

Suggested activity: compare pharmaceutical and diagnostic assets with a strategic-fit scorecard.
Suggested activity: convert diligence findings into a red-flag log, valuation adjustment, and decision gate.
Suggested activity: test milestone and royalty alternatives against risk-adjusted value.
Suggested activity: align negotiation positions with governance and transition responsibilities.

FAQs

Who suits life sciences business development training, and what does it assume?

Life sciences business development training suits professionals who already assess assets, partners, licensing opportunities, or alliances. It assumes familiarity with commercial evaluation and excludes legal, clinical, regulatory, and investment advice.

How does life sciences licensing training differ from general sales training?

Life sciences licensing training focuses on scientific assets, development risk, intellectual property, valuation, transaction terms, and alliance governance; general sales training focuses on prospecting, customer conversations, pipeline management, and closing.

How is risk-adjusted value used in biopharma licensing decisions?

Risk-adjusted value combines forecast cash flows with development timing, costs, technical success probabilities, and commercial assumptions. Teams use a defensible range and sensitivity analysis rather than treating one model output as a fixed transaction price.

What belongs in life sciences licensing due diligence?

Life sciences licensing due diligence combines scientific evidence, development plans, market assumptions, intellectual property position, partner capability, contractual obligations, financial inputs, and unresolved risks in a governed review process.

How should alliance governance follow a licensing deal?

Alliance governance should define decision rights, forums, information flows, performance measures, issue escalation, change control, and transition responsibilities so that both parties can manage delivery and revisit assumptions.

Conclusion

Participants take back a Life Sciences Partnering and Deal Portfolio. It connects a partnering thesis, asset screen, diligence plan, valuation range, negotiation mandate, term-sheet position, and alliance governance plan. The portfolio changes disconnected commercial analysis into a traceable decision process for reviewing biotechnology, pharmaceutical, and diagnostic opportunities.

credits: 5 credit per day

Course Mode: full-time

Provider: Agile Leaders Training Center

Download Brochure (PDF) Print PDF

Showing 1-20 of 76 events

Location	Dates	Duration	Mode	Price
Paris	Week 46, 2026 9 – 13 November 2026	1 Week	Onsite	€5,700
Trabzon	Week 46, 2026 15 – 19 November 2026	1 Week	Onsite	€6,800
Amman	Week 47, 2026 22 – 26 November 2026	1 Week	Onsite	€4,100
Abu Dhabi	Week 48, 2026 23 – 27 November 2026	1 Week	Onsite	€4,700
Milan	Week 49, 2026 30 November – 4 December 2026	1 Week	Onsite	€5,700
Frankfurt	Week 49, 2026 30 November – 4 December 2026	1 Week	Onsite	€5,700
Jakarta	Week 50, 2026 7 – 11 December 2026	1 Week	Onsite	€5,700
Doha	Week 50, 2026 13 – 17 December 2026	1 Week	Onsite	€5,500
Lagos	Week 50, 2026 13 – 17 December 2026	1 Week	Onsite	€4,100
Geneva	Week 51, 2026 20 – 24 December 2026	1 Week	Onsite	€6,200
London	Week 53, 2026 28 December 2026 – 1 January 2027	1 Week	Onsite	€5,700
Kuwait	Week 53, 2027 3 – 7 January 2027	1 Week	Onsite	€5,500
Milan	Week 01, 2027 4 – 8 January 2027	1 Week	Onsite	€5,700
Chicago	Week 01, 2027 10 – 14 January 2027	1 Week	Onsite	€12,000
Dubai	Week 02, 2027 11 – 15 January 2027	1 Week	Onsite	€4,500
Muscat	Week 02, 2027 17 – 21 January 2027	1 Week	Onsite	€5,700
Lisbon	Week 04, 2027 25 – 29 January 2027	1 Week	Onsite	€5,700
Cairo	Week 05, 2027 1 – 5 February 2027	1 Week	Onsite	€4,100
Abu Dhabi	Week 05, 2027 1 – 5 February 2027	1 Week	Onsite	€4,700
Istanbul	Week 06, 2027 8 – 12 February 2027	1 Week	Onsite	€4,500

Frequently asked questions

What does this course cover?

OverviewLife Sciences Business Development and Licensing Training Course is a one-week advanced course for professionals who leave with a Life Sciences Partnering and Deal Portfolio. Participants connect therapeutic-area strategy, scientific and commercial due diligence, intellectual property licensing, risk-adjusted net present value, negotiation, and an…

Are training dates available?

Yes. Available dates and destinations are listed in the course dates section on this page.

How can I register?

Choose an available date on this page and complete the registration form, or send a programme enquiry.

Can I download the course brochure?

Yes. Use the brochure download link provided on this page.

Life Sciences Business Development Training Course